Business Description
Immuneering Corp
NAICS : 325412
SIC : 2834
Description
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 24.15 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 4.79 | |||||
| Beneish M-Score | -5.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.65 | |||||
| 9-Day RSI | 51.41 | |||||
| 14-Day RSI | 46.32 | |||||
| 6-1 Month Momentum % | -32.74 | |||||
| 12-1 Month Momentum % | -60.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 16.54 | |||||
| Quick Ratio | 16.54 | |||||
| Cash Ratio | 16.15 | |||||
| Days Sales Outstanding | 179.61 | |||||
| Days Payable | 1686.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 27.87 | |||||
| Operating Margin % | -9659.29 | |||||
| Net Margin % | -9496.25 | |||||
| ROE % | -33.66 | |||||
| ROA % | -31.66 | |||||
| ROIC % | -370.71 | |||||
| ROC (Joel Greenblatt) % | -1020.16 | |||||
| ROCE % | -33.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 234.21 | |||||
| PB Ratio | 0.96 | |||||
| Price-to-Tangible-Book | 1.02 | |||||
| EV-to-EBIT | -0.11 | |||||
| EV-to-EBITDA | -0.11 | |||||
| EV-to-Revenue | 10.19 | |||||
| EV-to-Forward-Revenue | 20.49 | |||||
| EV-to-FCF | -0.12 | |||||
| Price-to-Net-Current-Asset-Value | 1.09 | |||||
| Price-to-Net-Cash | 1.12 | |||||
| Earnings Yield (Greenblatt) % | -909.09 |
